MediciNova Wins Contract Research and Development Innovation Award for MN-166 Treatment for Neurological Diseases

MediciNova has won the Contract Research and Development Innovation Award at the 2025 BioTech Breakthrough Awards for its work on MN-166 (ibudilast), a drug candidate for neurological diseases like ALS. The award recognizes MediciNova's innovative approach to developing disease-modifying therapies for conditions with few treatment options. The company's ongoing Phase 2/3 COMBAT-ALS trial of MN-166 in ALS patients is a key part of its mission to deliver meaningful breakthroughs for patients.